{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:56:06Z","timestamp":1760889366132},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Science Center in Poland","award":["2014\/13\/D\/NZ7\/00278"],"award-info":[{"award-number":["2014\/13\/D\/NZ7\/00278"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jpba.2017.03.023","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T15:17:13Z","timestamp":1489850233000},"page":"122-129","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Determination of prodrug treosulfan and its biologically active monoepoxide in rat plasma, liver, lungs, kidneys, muscle, and brain by HPLC\u2013ESI\u2013MS\/MS method"],"prefix":"10.1016","volume":"140","author":[{"given":"Micha\u0142","family":"Roma\u0144ski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kasprzyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Te\u017cyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Widerowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Czes\u0142aw","family":"\u017baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciszek","family":"G\u0142\u00f3wka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.03.023_bib0005","first-page":"6869","article-title":"Treosulfan in the treatment of advanced ovarian cancer \u2013 results of a German multicenter non-interventional study","volume":"35","author":"Chekerov","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jpba.2017.03.023_bib0010","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1182\/blood-2010-10-312082","article-title":"Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience","volume":"117","author":"Slatter","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2017.03.023_bib0015","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/bmt.2011.242","article-title":"Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning","volume":"47","author":"Casper","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jpba.2017.03.023_bib0020","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00277-012-1429-y","article-title":"Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10\/10 HLA-identical unrelated donor","volume":"91","author":"Michallet","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jpba.2017.03.023_bib0025","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","article-title":"Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial","volume":"96","author":"Ruutu","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jpba.2017.03.023_bib0030","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","article-title":"Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies","volume":"17","author":"Nemecek","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.jpba.2017.03.023_bib0035","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/pbc.25764","article-title":"European Society for Blood and Marrow Transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological malignancies","volume":"63","author":"Boztug","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jpba.2017.03.023_bib0040","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","article-title":"Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience","volume":"128","author":"Morillo-Gutierrez","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2017.03.023_bib0045","unstructured":"ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00822393?term=treosulfan, last accessed on 2 Dec 2016."},{"key":"10.1016\/j.jpba.2017.03.023_bib0050","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1021\/jm00300a034","article-title":"Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonat","volume":"13","author":"Feit","year":"1970","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2017.03.023_bib0055","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1002\/jps.24662","article-title":"Activation of prodrug treosulfan at pH 7.4 and 37\u00b0C accompanied by hydrolysis of its active epoxides: kinetic studies with clinical relevance","volume":"104","author":"Roma\u0144ski","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2017.03.023_bib0060","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.xphs.2016.03.001","article-title":"Formation rate-limited pharmacokinetics of biologically active epoxy transformers of prodrug treosulfan","volume":"105","author":"Roma\u0144ski","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2017.03.023_bib0065","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.bmt.1704784","article-title":"Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increasing risk for regimen-related complications","volume":"35","author":"Beelen","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jpba.2017.03.023_bib0070","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1038\/bmt.2008.287","article-title":"Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT","volume":"42","author":"G\u0142\u00f3wka","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jpba.2017.03.023_bib0075","first-page":"4209","article-title":"Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies","volume":"6","author":"Scheulen","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2017.03.023_bib0080","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpba.2011.12.021","article-title":"HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: pharmacokinetic application","volume":"62","author":"G\u0142\u00f3wka","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.03.023_bib0085","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/FTD.0000000000000047","article-title":"Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"36","author":"ten Brink","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2017.03.023_bib0090","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejps.2014.12.010","article-title":"Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT","volume":"68","author":"G\u0142\u00f3wka","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2017.03.023_bib0095","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.talanta.2014.03.067","article-title":"Rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of protein-free pro-drug treosulfan and its biologically active monoepoxy-transformer in plasma and brain tissue","volume":"127","author":"Roma\u0144ski","year":"2014","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2017.03.023_bib0100","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1124\/dmd.115.066050","article-title":"Penetration of treosulfan and its active monoepoxide transformation product into central nervous system of juvenile and young adult rats","volume":"43","author":"Roma\u0144ski","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2017.03.023_bib0105","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.dmpk.2016.07.001","article-title":"Ocular disposition of treosulfan and its active epoxy-transformers following intravenous administration in rabbits","volume":"31","author":"Roma\u0144ski","year":"2016","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jpba.2017.03.023_bib0110","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jpba.2012.10.005","article-title":"Direct high-performance liquid chromatography method with refractometric detection designed for stability studies of treosulfan and its biologically active epoxy-transformers","volume":"72","author":"G\u0142\u00f3wka","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.03.023_bib0115","unstructured":"Guideline on bioanalytical method validation \u2013 European Medicines Agency, 2011. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf, last accessed on 2 Dec 2016."},{"key":"10.1016\/j.jpba.2017.03.023_bib0120","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/jn\/135.7.1718","article-title":"Tissue distribution of quercetin in rats and pigs","volume":"135","author":"de Boer","year":"2005","journal-title":"J. Nutr."},{"key":"10.1016\/j.jpba.2017.03.023_bib0125","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/jcbfm.2009.200","article-title":"Improved measurement of drug exposure in the brain using drug-specific correction for residual blood","volume":"30","author":"Frid\u00e9n","year":"2010","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jpba.2017.03.023_bib0130","unstructured":"Codeine \u2013 Drug Bank. Available at: https:\/\/www.drugbank.ca\/drugs\/DB00318, last accessed on 8 Dec 2016."},{"key":"10.1016\/j.jpba.2017.03.023_bib0135","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00280-007-0566-9","article-title":"Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma","volume":"62","author":"Werner","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl. 4","key":"10.1016\/j.jpba.2017.03.023_bib0140","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1289\/ehp.97105s4791","article-title":"The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics","volume":"105","author":"Seidegard","year":"1997","journal-title":"Environ. Health. Perspect."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517300560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517300560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T18:54:48Z","timestamp":1568919288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708517300560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":28,"alternative-id":["S0731708517300560"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.03.023","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of prodrug treosulfan and its biologically active monoepoxide in rat plasma, liver, lungs, kidneys, muscle, and brain by HPLC\u2013ESI\u2013MS\/MS method","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}